source
- Entrada shares dive as Duchenne results disappointWhile the company claimed a victory, analysts said data from a Phase 1/2 study fell short of expectations. Entrada shares subsequently tumbled more than 50%.BioPharma Dive · 2mo ago↗ source
- Entrada stock falls on Duchenne data; Wegovy expands accessPlus, news about BioCryst, GSK and Roche. 🙃 Entrada’s Duchenne drug disappoints: The biotech reported initial data in six patients who received the low dose of its exon 44 skipping drug ...Endpoints · 2mo ago↗ source
- Roche to acquire digital pathology firm PathAI in deal potentially worth over $1BRoche plans to offer PathAI’s tools as part of an effort to improve cancer diagnosis and tailored treatment.BioPharma Dive · 2mo ago↗ source